Q1 2025 Earnings Call Transcript May 8, 2025 Operator: Good day and welcome to the Delcath Systems’ First Quarter 2025 ...

A young mum diagnosed with incurable cancer just weeks after giving birth to her son has completed the first cycle of a £200,000 treatment regime.

PRNewswire/ -- iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today announces it has dosed the ...

The Company continues its ongoing partnerships with IMPACT Melanoma, AIM at Melanoma and Melanoma Research Foundation to drive education and awarenes ...

Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year ...

March 31, 2025, and an updated cash runway guidance into 2029; commercial readiness activities ongoing Over 300 patients enrolled in darovasertib and crizotinib registrational 1L HLA-A2-negative MUM ...

"We are excited about joining Castle,” said Daniel Lunz, chief executive officer of Previse. "We look forward to the advancements to care we can make together for patients with GI diseases-our ...

A new drug application seeking the approval of ziftomenib was submitted to the FDA on April 8, 2025. This indication is for ...

Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on ...

Detailed price information for Castle Biosciences Inc (CSTL-Q) from The Globe and Mail including charting and trades.

Immunocore Holdings' stock has dropped 60% as Kimmtrak faces market saturation, but its pipeline could offer potential. Find ...